Loading news...
Baillie Gifford and Co. boosted its stake in shares of RxSight, Inc. (NASDAQ: RXST) by 46.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 686,316 shares of the company's stock after purchasing an additional 217,371
RxSight, Inc. (NASDAQ: RXST - Get Free Report) has received a consensus rating of "Reduce" from the thirteen ratings firms that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and one has given a buy recommendation to the company. The
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
RxSight, Inc. (RXST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition.
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Carnegie Lake Advisors LLC boosted its position in shares of RxSight, Inc. (NASDAQ: RXST) by 81.6% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 194,345 shares of the company's stock after purchasing an additional 87,345 shares during the period. Carnegie Lake Advisors
ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thunen, the Company's Chief Financial Officer, is transitioning from her role. Ms. Thunen will remain with the Company until the sooner of the appointment of her successor or January 31, 2026. Ms. Thunen has agreed to support the Company as a consultant subsequent to the transition.
Thrivent Financial for Lutherans decreased its holdings in RxSight, Inc. (NASDAQ: RXST) by 30.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 312,220 shares of the company's stock after selling 139,382 shares during the period. Thrivent Financial for Lutherans
ALISO VIEJO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – November 20, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York City.
RxSight, Inc. ( RXST ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Oliver Moravcevic Ronald Kurtz - Co-President, CEO & Director Shelley Thunen - Co-President & CFO Conference Call Participants Iseult McMahon - BTIG, LLC, Research Division David Saxon - Needham & Company, LLC, Research Division Gursimran Kaur - Wells Fargo Securities, LLC, Research Division Patrick Wood - Morgan Stanley, Research Division K. Gong - JPMorgan Chase & Co, Research Division Adam Maeder - Piper Sandler & Co., Research Division Danielle Antalffy - UBS Investment Bank, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Hello, everyone.
RxSight, Inc. (RXST) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to break-even earnings per share a year ago.
ALISO VIEJO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2025.